The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study.

Kaplan Meier analysis revealed a significantly reduced risk of all-cause mortality, while the reduction in composite kidney outcome showed only a trend and did not reach statistical significance ( P = 0.00095, P = 0.065, respectively).

also in 111,027 other papers

However, after accounting for mortality as a competing risk, only a strong trend toward risk reduction was observed, which did not reach statistical significance (aHR 0.74 95% CI 0.55–1; P −0.053) (Supplementary Table S3).

also in 5,725 other papers